Entrada Therapeutics, Inc.
NASDAQ: TRDABoston, US · Founded 2016 · Delaware corporation · 5 known investors
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
Founders & leadership
NK
Nerissa KreherExecutive
KW
Kory WentworthinExecutive
DD
Dipal DoshiinChief Executive Officer
ND
Nathan DowdenExecutive
NS
Natarajan Sethuraman, PhDPresident of Research and Development
NJ
Nathan J. DowdeninPresident and Chief Operating Officer
KW
Kory Wentworth, CPAChief Financial Officer
JC
Jared Cohen, PhD, JDinGeneral Counsel
KM
Karla MacDonaldinChief Corporate Affairs Officer
NS
Natarajan SethuramaninNamed on SEC filing
Board
CN
KM
Investors · 5
Reported raises · per SEC filings
Form D private placements$150.9M disclosed across 3 rounds · 2016–2021
▶$116.2MraisedApr 2021 · 26 investors · BiotechnologyRule 506(b)
▶$116.2MraisedApr 2021 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carole NuechterleinDirector
- Natarajan SethuramanExecutive Officer
- Kush M. ParmarDirector
- Todd FoleyDirector
- Peter KimDirector
- Nerissa KreherExecutive Officer
- Kory WentworthExecutive Officer
- Dipal DoshiExecutive Officer, Director
- John F. CrowleyDirector
- Nathan DowdenExecutive Officer
- Offering amount
- $116.2M
- Amount sold
- $116.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$34MraisedDec 2019 · 10 investors · PharmaceuticalsRule 506(b)
▶$34MraisedDec 2019 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Natarajan SethuramanExecutive Officer
- John CrowleyDirector
- Nathan DowdenExecutive Officer
- Louis TartagliaDirector
- Kush ParmarDirector
- Christine BrennanDirector
- Anja HarmeierDirector
- Dipal DoshiExecutive Officer, Director
- Todd FoleyDirector
- Mario SaltarelliExecutive Officer
- Offering amount
- $59M
- Amount sold
- $34M
- Proceeds to insiders
- $3.4M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$600KraisedNov 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$600KraisedNov 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kush ParmarExecutive Officer, Director
- Louis TartagliaExecutive Officer, Director
- Dehua PeiDirector
- Offering amount
- $1.6M
- Amount sold
- $600K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Entrada Therapeutics, Inc. went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Entrada Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Entrada Therapeutics, Inc. do?
- Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
- Who are Entrada Therapeutics, Inc.'s investors?
- Entrada Therapeutics, Inc.'s investors include 5AM Ventures, MPM BioImpact, Roche Venture Fund, TCG Crossover, Agent Capital.
- How much funding has Entrada Therapeutics, Inc. raised?
- Entrada Therapeutics, Inc. has disclosed $150.9M raised across 3 rounds.
- Where is Entrada Therapeutics, Inc. headquartered?
- Entrada Therapeutics, Inc. is headquartered in Boston, US.